Literature DB >> 18054145

Opioids for persistent noncancer pain.

Gary McCleane1, Howard S Smith.   

Abstract

This article concentrates on recent evidence about opioid analgesics for persistent noncancer pain. Evidence confirms that opioids are drugs with a definite risk of adverse events. Therefore, before prescribing opioids, careful consideration must be given to be certain that the intended benefit of a particular opioid merits its use despite the potential side effects and to determine if the co-prescription of other pharmacologic agents could reduce the risk of adverse events. Strong opioids should be reserved for patients who fail to respond to other lower-risk options and only after proper consideration is given to the long-term consequences of strong opioid use. Problems associated with opioids dictate that more efficacious and safer drugs need to be found.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054145     DOI: 10.1016/j.anclin.2007.08.002

Source DB:  PubMed          Journal:  Anesthesiol Clin        ISSN: 1932-2275


  3 in total

1.  Shared mechanisms for opioid tolerance and a transition to chronic pain.

Authors:  Elizabeth K Joseph; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

2.  Clinical efficacy of OROS® hydromorphone in patients suffering from severe chronic pain: A Study undertaken in routine clinical practice.

Authors:  Aleksander Stepanović; Jelka Pirc; Slavica Lahajnar Čavlović
Journal:  Wien Klin Wochenschr       Date:  2011-06-28       Impact factor: 1.704

3.  N-Pyrazoloyl and N-thiopheneacetyl hydrazone of isatin exhibited potent anti-inflammatory and anti-nociceptive properties through suppression of NF-κB, MAPK and oxidative stress signaling in animal models of inflammation.

Authors:  Sara Zeeshan; Muhammad Naveed; Adnan Khan; Ayesha Atiq; Maryam Arif; Muhammad Naeem Ahmed; Yeong Shik Kim; Salman Khan
Journal:  Inflamm Res       Date:  2019-05-11       Impact factor: 4.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.